1034 related articles for article (PubMed ID: 18687920)
21. A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain.
Goggi JL; Lewis HD; Mok J; Harrison T; Shearman MS; Atack JR; Best JD
J Neurosci Methods; 2006 Oct; 157(2):246-52. PubMed ID: 16859750
[TBL] [Abstract][Full Text] [Related]
22. Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice.
Philipson O; Lannfelt L; Nilsson LN
FEBS Lett; 2009 Sep; 583(18):3021-6. PubMed ID: 19683527
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
24. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation.
Jäger S; Leuchtenberger S; Martin A; Czirr E; Wesselowski J; Dieckmann M; Waldron E; Korth C; Koo EH; Heneka M; Weggen S; Pietrzik CU
J Neurochem; 2009 Dec; 111(6):1369-82. PubMed ID: 19804379
[TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
26. Measuring APP carboxy-terminal fragments.
Esposito LA
Methods Mol Biol; 2011; 670():71-84. PubMed ID: 20967584
[TBL] [Abstract][Full Text] [Related]
27. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
28. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
29. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
[TBL] [Abstract][Full Text] [Related]
30. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein.
Irizarry MC; Deng A; Lleo A; Berezovska O; Von Arnim CA; Martin-Rehrmann M; Manelli A; LaDu MJ; Hyman BT; Rebeck GW
J Neurochem; 2004 Sep; 90(5):1132-43. PubMed ID: 15312168
[TBL] [Abstract][Full Text] [Related]
32. [Biological characteristics of amyloid precursor protein and Alzheimer's disease].
Fukatsu R; Tsuzuki K; Takamaru Y; Hayashi Y; Sasaki N; Yoshida T; Midorikawa Y; Fujii N; Takahata N
Rinsho Byori; 1996 Mar; 44(3):213-24. PubMed ID: 8857163
[TBL] [Abstract][Full Text] [Related]
33. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
34. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
Kurt MA; Davies DC; Kidd M; Duff K; Rolph SC; Jennings KH; Howlett DR
Exp Neurol; 2001 Sep; 171(1):59-71. PubMed ID: 11520121
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice.
Zohar O; Pick CG; Cavallaro S; Chapman J; Katzav A; Milman A; Alkon DL
Neurobiol Aging; 2005; 26(8):1167-75. PubMed ID: 15917100
[TBL] [Abstract][Full Text] [Related]
36. Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms.
Cater MA; McInnes KT; Li QX; Volitakis I; La Fontaine S; Mercer JF; Bush AI
Biochem J; 2008 May; 412(1):141-52. PubMed ID: 18248325
[TBL] [Abstract][Full Text] [Related]
37. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
38. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells.
Peng Y; Jiang L; Lee DY; Schachter SC; Ma Z; Lemere CA
J Neurosci Res; 2006 Sep; 84(4):903-11. PubMed ID: 16862548
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
40. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
